“We closed the first quarter of 2024 with EUR 300.2 million in cash and cash equivalents. During this quarter, we fully settled the raw material commitments related to CVnCoV, our first-generation SARS-CoV-2 vaccine candidate,” said Pierre Kemula, Chief Financial Officer of CureVac. “More than half of the cash spent in the first three months was related to such commitments. Looking forward, we consider this the end of a strong Q1 spend seasonality for CureVac. The second quarter will see the end of the remaining CVnCoV-related contract termination provisions. Together with the ongoing organizational redesign, we anticipate a significantly lower cash burn in the future.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVAC:
- CureVac price target lowered to $14 from $18 at UBS
- Curevac’s Market Forecast Risks: Miscalculations and Trial Participant Challenges Threaten Profitability
- CureVac downgraded to Market Perform from Outperform at Leerink
- CureVac N.V. Reports Strong 2023 Finances and Strategic Advances
- CureVac Launches Study for H5N1 Influenza Vaccine
